SCHEMBL1641995

SCHEMBL1641995

C[C@H](c1ccccc1)n1cc(C(=O)NC2CCCCC2)c(O)c(C(=O)NCC(=O)O)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.50
EGLN3 Q9H6Z9 2/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
GAA P10253 1/20 0.44
PPARG P37231 1/20 0.44
NCOA2 Q15596 1/20 0.44
EGLN1 Q9GZT9 2/20 0.42
BBOX1 O75936 1/20 0.42
ASPH Q12797 1/20 0.42
KDM8 Q8N371 1/20 0.42
IDH1 O75874 2/20 0.42
CNR1 P21554 3/20 0.42
CNR2 P34972 3/20 0.42
OGFOD1 Q8N543 1/20 0.41
EGLN2 Q96KS0 1/20 0.41
HIF1AN Q9NWT6 1/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641463 1.00 BRD4 (0.50) BRD4EGLN3NPC1RAB9AGAA
SCHEMBL12768419 0.86 EGLN3 (0.42) EGLN3NPC1RAB9AGAAPPARG
SCHEMBL1642253 0.82 NPC1 (0.50) EGLN3NPC1RAB9AGAAPPARG
SCHEMBL1641918 0.80 EGLN3 (0.70) BRD4EGLN3CNR1CNR2
SCHEMBL1642795 0.79 EGLN3 (0.71) BRD4EGLN3EGLN1CNR1CNR2
SCHEMBL1642043 0.78 EGLN1 (0.47) EGLN3NPC1RAB9AGAAPPARG
SCHEMBL1642747 0.78 EGLN1 (0.50) EGLN3NPC1RAB9AGAAPPARG
SCHEMBL1641138 0.78 EGLN1 (0.50) EGLN3NPC1RAB9AGAAPPARG
SCHEMBL1642791 0.78 EGLN1 (0.50) EGLN3NPC1RAB9AGAAPPARG
SCHEMBL1641882 0.77 EGLN1 (0.48) EGLN3NPC1RAB9AGAAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 BRD4 3195/4885EGLN3 3/4885NPC1 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.